Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 325 of 2051 entries
View as:

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

Phase: N/A Priority: Normal
NCT ID: NCT03598608 Org: User:
Start: 10/17/18 End: 01/16/26 Due: 01/16/27

A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)

Phase: N/A Priority: Normal
NCT ID: NCT01650727 Org: User:
Start: 10/31/12 End: 10/31/13 Due: 10/31/14

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00496626 Org: User:
Start: 07/20/08 End: 02/28/09 Due: 02/28/10

A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00886600 Org: User:
Start: 05/31/91 End: 08/31/92 Due: 08/31/93

Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)

Phase: N/A Priority: Normal
NCT ID: NCT00034658 Org: User:
Start: 12/31/98 End: 03/31/02 Due: 03/31/03

MK0524 Asthma POC Study (0524-008)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00783601 Org: User:
Start: 10/31/04 End: 05/31/05 Due: 05/31/06

A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

Phase: N/A Priority: Normal
NCT ID: NCT02039674 Org: User:
Start: 02/21/14 End: 10/18/21 Due: 10/18/22

Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402)

Phase: N/A Priority: Normal
NCT ID: NCT01278485 Org: User:
Start: 05/31/11 End: 06/30/12 Due: 06/30/13

A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)

Phase: N/A Priority: Normal
NCT ID: NCT02036502 Org: User:
Start: 02/14/14 End: 03/19/20 Due: 03/19/21

Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)

Phase: N/A Priority: Normal
NCT ID: NCT04665050 Org: User:
Start: 02/04/21 End: 04/06/21 Due: 04/06/22

A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)

Phase: N/A Priority: Normal
NCT ID: NCT02411929 Org: User:
Start: 10/29/14 End: 02/09/15 Due: 02/09/16

Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

Phase: N/A Priority: Normal
NCT ID: NCT04295772 Org: User:
Start: 11/26/20 End: 01/25/23 Due: 01/25/24

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

Phase: N/A Priority: Normal
NCT ID: NCT02641067 Org: User:
Start: 01/26/16 End: 05/25/16 Due: 05/25/17

A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

Phase: N/A Priority: Normal
NCT ID: NCT01225731 Org: User:
Start: 10/25/10 End: 10/24/12 Due: 10/24/13

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

Phase: N/A Priority: Normal
NCT ID: NCT01840579 Org: User:
Start: 04/26/13 End: 02/28/20 Due: 02/28/21

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

Phase: N/A Priority: Normal
NCT ID: NCT02335424 Org: User:
Start: 02/24/15 End: 02/18/22 Due: 02/18/23

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Phase: N/A Priority: Normal
NCT ID: NCT01329913 Org: User:
Start: 05/31/11 End: 04/30/12 Due: 04/30/13

A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)

Phase: N/A Priority: Normal
NCT ID: NCT01379300 Org: User:
Start: 05/31/11 End: 12/31/11 Due: 12/31/12

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

Phase: N/A Priority: Normal
NCT ID: NCT00395421 Org: User:
Start: 10/31/06 End: 08/31/08 Due: 08/31/09

A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT00851266 Org: User:
Start: 10/31/06 End: 01/31/09 Due: 01/31/10

A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797)

Phase: N/A Priority: Normal
NCT ID: NCT00124735 Org: User:
Start: 10/31/04 End: 09/30/07 Due: 09/30/08

Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)

Phase: N/A Priority: Normal
NCT ID: NCT00705198 Org: User:
Start: 09/30/06 End: 07/31/16 Due: 07/31/17

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Phase: N/A Priority: Normal
NCT ID: NCT01021748 Org: User:
Start: 11/23/09 End: 07/16/14 Due: 07/16/15

Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)

Phase: N/A Priority: Normal
NCT ID: NCT03374254 Org: User:
Start: 02/16/18 End: 07/18/23 Due: 07/18/24

A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)

Phase: N/A Priority: Normal
NCT ID: NCT01354990 Org: User:
Start: 02/28/09 End: 05/31/10 Due: 05/31/11